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STATEMENT OF INTEREST OF AMICI CURIAE 
 Amici curiae submit this brief pursuant to Fed. R. App. P. 29 and Rule 
29 of this court.  All parties have consented to the filing of this brief.  
 Amici are professors who teach and/or write about biotechnology patent 
law at universities throughout the United States.  A list of amici appears at 
Appendix A.  No part of this brief was authored by counsel for any party, 
person, or organization besides amici.  No other person has contributed 
money that was intended to fund preparing or submitting this brief.    
 Amici represent no institution, group, or association and have no 
personal interest or stake in the outcome of this case.  Our sole interest in 
this case is furtherance of the patent system’s constitutional purpose of 
“promot[ing] the Progress of Science and useful Arts.”   
 This brief is filed to present to the court an argument that (1) the 
novelty and nonobviousness analyses of patent claims directed to DNA 
oligonucleotides (short DNA molecules) are uniquely susceptible to 
diversion into considerations unrelated to progress in the field of 
biotechnology; and (2) such analyses should be pre-empted by holding DNA 
oligonucleotides to be unpatentable under the printed matter doctrine.
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SUMMARY OF ARGUMENT 
 The isolated DNA oligonucleotide compositions (short DNA 
molecules) claimed in claims 5 and 6 of U.S. Patent No. 5,747,282 can be 
synthesized by general methods that have been widely known and used since 
at least the early 1980s.  A pre-1993 publication describing these methods 
and listing any of the claimed oligonucleotide sequences would have 
anticipated and invalidated these claims under § 102(b).  Yet it is trivial (and 
was trivial then) to computer-generate and publish a list of all 
oligonucleotide sequences of a given length, provided that such a list can be 
stored feasibly on a medium that can be made accessible to the public.  Thus 
the novelty of DNA oligonucleotide claims hinges largely on whether 
structural definitions of the claimed sequences have previously been typed 
out as A’s, C’s, G’s and T’s in such a computer-generated list and published.  
Such a consideration has more to do with the norms of the scientific 
community regarding scholarly communication and with the availability of 
low-cost, high-capacity information storage media, than with the state of the 
art in biotechnology. 
 Amici contend that the patentability analysis of DNA oligonucleotide 
claims should not reach these irrelevant considerations, because DNA 
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oligonucleotides should be held ineligible for patenting under patent law’s 
printed matter doctrine.  The printed matter doctrine serves to pre-empt 
inapposite analyses of differences between the claimed invention and the 
prior art — e.g., analyses focused on the management of stored information 
rather than on the field of invention — that would otherwise be applied 
under the novelty doctrine of § 102 or the nonobviousness doctrine of § 103. 
 The printed matter doctrine is applicable to the claimed 
oligonucleotides because DNA oligonucleotide molecules are disposed to 
store nucleotide sequence information in a manner analogous in all relevant 
respects to other substrates that may be more intuitively recognizable as 
information storage media, such as laser-printed text on paper.  Moreover, to 
the extent that a hybridization reaction involving a claimed oligonucleotide 
is recognized as having specific and substantial utility, it is by virtue of the 
semantic properties that scientists have attached to the complementary DNA 
sequence, not an inventive functional relationship between the sequence 
information and its molecular substrate.  While hybridization reactions 
involving the claimed oligonucleotide probes may impart new and 
unobvious information regarding cancer, such information is useful and 
intelligible only to the human mind and cannot confer patentability.   
 3
 
 
ARGUMENT 
 
I. The Focus of this Brief Is Limited 
 The focus of this brief is directed solely to the patentability of short 
DNA molecules, also known as oligonucleotides, such as those claimed in 
claims 5 and 6 of U.S. Patent No. 5,747,282.1  Amici contend that both of 
these claims should be held invalid under the printed matter doctrine.  Amici 
take no position with respect to (1) the patentability of any other claims in 
issue in this case or (2) the applicability of the product of nature doctrine to 
claims 5 and 6. 
                                           
1
 Claims 5 and 6, both dependent claims, read:  “An isolated DNA having at 
least 15 nucleotides of the DNA of claim 1” and “An isolated DNA having 
at least 15 nucleotides of the DNA of claim 2,” respectively.  Corresponding 
independent claims 1 and 2 are directed to longer DNA molecules.  Claim 1 
reads: “An isolated DNA coding for a BRCA1 polypeptide, said polypeptide 
having the amino acid sequence set forth in SEQ ID NO:2.”  Claim 2 reads: 
“The isolated DNA of claim 1, where said DNA has the nucleotide sequence 
set forth in SEQ ID NO:1.” 
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II. The Printed Matter Doctrine Precludes the Awarding of Patents  
for Inventive Contributions That Subsist Merely in Stored 
Information 
 
 The printed matter doctrine states that “‘[m]ere printed matter can not 
impart a patentable feature to a claim.’” In re Gulack, 703 F.2d 1381, 1385 
(Fed. Cir. 1983) (quoting In re Miller, 418 F.2d 1392 (C.C.P.A.1969)).  The 
doctrine does not apply, however, when there is a “new and unobvious 
functional relationship between the printed matter and the substrate.”  703 
F.2d at 1386. 
 As Judge Linn explained in In re Nuijten, 500 F.3d 1346 (Fed. Cir. 
2007), the printed matter doctrine precludes patentability where the 
differences between the claimed invention and the prior art subsist merely in 
stored information: 
Under the “printed matter” doctrine, if the only distinction 
between a prior art storage medium and a claimed storage medium 
is the information stored thereon — rather than a different 
“functional relationship between the printed matter and the 
substrate” — then the claimed storage medium (with associated 
information) is unpatentably obvious over the prior art because the 
information lacks “patentable weight.” 
 
Id. at 1365 (Linn, J., concurring-in-part and dissenting-in-part).  
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A.  The Printed Matter Doctrine Extends to All Information 
Storage Media 
 
 The printed matter doctrine has survived the progression of printing 
technologies from typewriters and treadle presses to laser printers and 
nanolithography without having been limited to any particular kind of 
storage medium.  See id.  Instead, it extends to any physical substrate 
capable of holding information, subject to the “functional relationship” 
limitation noted above.  Accordingly, courts over the years have proceeded 
to apply the doctrine and its accompanying limitation in cases involving a 
wide range of substrates.  See, e.g., In re Bryan, 323 Fed.Appx. 898 (Fed. 
Cir. 2009) (unpublished) (game boards); In re Gulack, 703 F.2d 1381 (Fed. 
Cir. 1983) (paper, fabric or plastic bands); In re Miller, 418 F.2d 1392 
(C.C.P.A.1969) (measuring cups and spoons); Ex parte Gwinn, 112 U.S.P.Q. 
439 (B.P.A.I 1955) (dice in a “parlor golf game”); In re Kothny, 96 F.2d 289 
(C.C.P.A. 1938) (scales for measuring cylindrical records); In re McKee, 75 
F.2d 991 (C.C.P.A. 1935) (meat products); In re Johns, 70 F.2d 913 
(C.C.P.A. 1934) (animal carcasses); In re Sterling, 70 F.2d 910 (C.C.P.A. 
1934) (checkbooks); Cincinnati Traction Co. v. Pope, 210 F. 443 (6th Cir. 
1913) (trolley transfer tickets). 
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B.  The Printed Matter Doctrine Serves to Pre-empt Inapposite  
Novelty and Nonobviousness Analyses  
 
 The printed matter doctrine has traditionally been viewed as an 
elaboration of the § 101 patentable subject matter requirement, see 1 CHISUM 
ON PATENTS § 1.02[4], at 1-24 (2006) (“‘[P]rinted matter’ by itself did not 
constitute a ‘manufacture’”); see also Examination Guidelines for 
Computer-Related Inventions, 61 Fed. Reg. 7478, 7481 (Feb. 28, 1996) 
(instructing examiners to reject non-functional descriptive material under 
§ 101).  The doctrine’s reliance on “patentable weight” considerations, 
however, is more akin to a Graham analysis of the nonobviousness of the 
“differences between the prior art and the claims at issue,” Graham v. John 
Deere Co., 383 U.S. 1, 17-18 (1966), than the “claim as a whole” approach 
that pervades modern patentable subject matter doctrine, see Diamond v. 
Diehr, 450 U.S. 175, 189-91 (1981).  Accordingly, the printed matter 
doctrine has also sometimes been applied as part of a § 102 or § 103 
analysis.  See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004); In re Gulack, 
703 F.2d 1381 (Fed. Cir. 1983); see also In re Nuijten, 500 F.3d 1346, 1365 
(Fed. Cir. 2007) (Linn, J., concurring-in-part and dissenting-in-part) 
 7
 
 
(characterizing the doctrine as supporting a conclusion of obviousness).  
Despite this ambiguous statutory locus, the printed matter doctrine has 
survived to the present day.  See infra section II.C. 
 As this court recently explained in King Pharmaceuticals, Inc. v. Eon 
Labs., 616 F.3d 1267 (Fed. Cir. 2010), the rationale behind the printed 
matter cases is “preventing the indefinite patenting of known products by the 
simple inclusion of novel, yet functionally unrelated limitations.”  Id. at 
1279.  The printed matter doctrine guards against the diversion of 
patentability analysis into assessments of the novelty and nonobviousness of 
information fixed in, but not conferring new and nonobvious functionality 
upon, the underlying substrate. 
 In so doing, the printed matter doctrine serves alongside the judicially 
created exceptions to patentable subject matter to pre-empt inapposite 
analyses of differences between the claimed invention and the prior art that 
would otherwise be applied under the novelty doctrine of § 102 and/or the 
nonobviousness doctrine of § 103.  Cf. Kevin E. Collins, Semiotics 101: 
Taking the Printed Matter Doctrine Seriously, 85 IND. L.J. 1379, 1387 
(2010) (explaining that the doctrine in effect “excludes certain useful and 
nonobvious products of human ingenuity from the patent regime”).  Courts 
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do not inquire into the nonobviousness of newly discovered natural 
principles, because “the discovery of some of the handiwork of nature . . . is 
not patentable . . . however ingenious the discovery of that natural principle 
may have been.”  Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 
131 (1948).  Similarly, where “the only distinction between a prior art 
storage medium and a claimed storage medium is the information stored 
thereon,” Nuijten, 500 F.3d at 1365, a Graham analysis of the 
nonobviousness of the “differences between the prior art and the claims at 
issue” would entail inquiries into the nonobviousness of the stored 
information relative to prior art stored information and the level of ordinary 
skill in information recombination, regardless of the field of the underlying 
invention.  See Graham v. John Deere Co., 383 U.S. at 17-18. 
 Courts have consistently regarded such information-management 
considerations as inapposite to the assessment of inventive contributions in 
the relevant field of endeavor.  For example, In re Russell, 48 F.2d 668 
(C.C.P.A. 1931) dealt with a directory in which surnames were arranged 
phonetically.  The applicant argued that his invention comprised “finished 
tangible subject matter bearing specifically arranged data or means, 
combined to produce a novel result.”  Id. at 668.  The court affirmed the 
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Patent Office’s rejection, holding: “The mere arrangement of printed matter 
on a sheet or sheets of paper, in book form or otherwise, does not constitute 
‘any new and useful art, machine, manufacture or composition of matter.’”  
Id. at 669.  This expression of the printed matter doctrine served to obviate 
an irrelevant inquiry into the novelty and nonobviousness of the applicant’s 
“finished tangible” directory as an information source relative to prior art 
directory and phonetic information sources. 
 Similarly, in Guthrie v. Curlett, 10 F.2d 725 (2d Cir. 1926), the 
patentee asserted a claim to a “consolidated tariff index” that compiled the 
shipping rates set by numerous transportation companies, using a system of 
symbols to facilitate a compact presentation.  Id. at 725.  The court credited 
the patentee with showing “how to compress into small space a lot of 
information about freight tariffs,” but explained that the proper subject of the 
patentability inquiry was the “means . . . for making a consolidated index.”  
Id. at 726.  Finding the disclosed means to consist solely of the non-novel 
“employment of symbols,” the court concluded that the claim was directed 
to unpatentable subject matter.  Id.  The court thereby refrained from an 
inapposite inquiry into the ability of one skilled in the art to combine and 
compress the information from prior art individual tariff schedules into a 
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single compact document. 
 In In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004), the applicant invented a 
new procedure for normalizing and amplifying RNA using a known reagent.  
Id. at 1337.  The Patent Office allowed his method claims, but rejected a 
claim directed to a kit combining the reagent with instructions for 
performing the new procedure.  Id. at 1337-38.  This court affirmed the 
rejection under the printed matter doctrine, finding that the claimed 
invention amounted to “the addition of new printed matter to a known 
product” with no functional relationship between the two:  “Here the printed 
matter in no way depends on the kit, and the kit does not depend on the 
printed matter.  All that the printed matter does is teach a new use for an 
existing product. . . .  If we were to adopt [applicant’s] position, anyone 
could continue patenting a product indefinitely provided that they add a new 
instruction sheet to the product.”  Id. at 1338-39.  The court’s application of 
the printed matter doctrine thereby avoided a Graham inquiry as to whether 
one of ordinary skill would have been able to assemble the claimed kit from 
the prior art — a task that would entail producing and storing instructions for 
a new and nonobvious procedure.  See id. at 1338 (noting applicant’s 
attempt to distinguish the kit claim by “argu[ing] that . . . prior art does not 
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teach a limitation of ‘instructions describing the method of [the method 
claim],’ combined with an amplification kit”). 
 Patent law’s novelty and nonobviousness doctrines are particularly ill-
suited to fact-specific assessments of the inventiveness embodied in stored 
information, because these doctrines artificially construct the knowledge of 
the person having ordinary skill in the art as including all publicly accessible 
information resources, no matter how obscure.  See, e.g., In re Hall, 781 F.2d 
897 (Fed. Cir. 1986) (finding that “a single cataloged thesis in one university 
library” was sufficiently accessible to one exercising reasonable diligence to 
constitute a § 102(b) “printed publication”).  By obviating an analysis 
directed to stylized facts and inapposite information-management 
considerations, the printed matter doctrine preserves the integrity of the 
novelty and nonobviousness doctrines as promoters of progress in the useful 
arts. 
  
C. The Supreme Court's Decision in Bilski v. Kappos Did Not 
Disturb the Printed Matter Doctrine 
 
 The printed matter doctrine is a long-established principle of patent law 
that survived the enactment of the 1952 Patent Act.  See, e.g., In re Miller, 
 12
 
 
418 F.2d 1392 (C.C.P.A. 1969); In re Russell, 42 F.2d 668 (C.C.P.A. 1931); 
U.S. Credit System Co. v. Am. Credit Indemnity Co., 59 F. 139, 143 (2d Cir. 
1893); see generally Harold C. Wegner, The Disclosure Requirements of the 
1952 Patent Act: Looking Back and a New Statute for the Next Fifty Years, 
37 AKRON L. REV. 243, 243 (2004) (“The great bulk [of the 1952 Act] was a 
mere codification of principles, going back in some cases to the earliest 
patent laws of the eighteenth century ....”).  While there is some ambiguity 
today as to which section of the 1952 Act supplies its statutory basis, see 
supra section II.B, the doctrine has never been repudiated in over a century.  
See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004).   
 In particular, the Supreme Court’s recent decision in Bilski v. Kappos, 
130 S.Ct. 3218 (June 28, 2010) did not disturb the printed matter doctrine, 
not least because the doctrine does not arise solely in connection with claims 
to § 101 “process[es].”  See CHISUM, supra (“‘[P]rinted matter’ by itself did 
not constitute a ‘manufacture’”).  Moreover, none of the Court’s reasoning 
in Bilski affects the operation of the printed matter doctrine.   
 As discussed in Section II.B supra, the printed matter doctrine’s 
functional role in preempting inapposite analyses of differences between the 
claimed invention and the prior art is essentially complementary to that of 
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the judicially created exceptions to patentable subject matter affirmed in 
Bilski and Diehr.  Thus, even though the Supreme Court in these decisions 
has required an “invention as a whole” approach to § 101 patent-eligible 
subject matter analysis, see Bilski, 130 S.Ct. at 3230 (citing Diehr, 450 U.S. 
at 188), this requirement has not affected the printed matter doctrine’s 
reliance on “patentable weight” considerations, as the post-Diehr decisions 
of this court plainly show.  See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 
2004).  Since Bilski, this court has continued to treat the printed matter 
doctrine as operative and relevant to patentability analysis.  See King 
Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1278-79 (Fed. Cir. 
Aug. 2, 2010) (citing printed matter cases as persuasive authority for point-
of-novelty analysis of method claim). 
 The Bilski Court clarified that the only exceptions to patentable subject 
matter supported by the Court’s precedents are for laws of nature, physical 
phenomena, and abstract ideas, 130 S.Ct. at 3226, definitively retiring the 
idea of a categorical exclusion for business methods.  Id. at 3228.  The 
printed matter doctrine’s precedential support, however, is in no way 
undermined by the Court’s repudiation of the supposed “business method” 
exception. 
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 It may be observed that the printed matter doctrine originated in part 
from cases involving printed business forms.  See, e.g., Hotel Security 
Checking Co. v. Lorraine, 160 F. 467 (2d Cir. 1908); United States Credit 
System Co. v. American Credit Indemnity Co., 59 F. 139 (2d Cir. 1893).  The 
applicability of the doctrine, however, has never been limited to business 
methods.  See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004).  Moreover, 
since the early business-form cases, the role of the printed matter doctrine 
has developed independently of any putative justification for excluding the 
category of business methods from patentability.  See, e.g., In re Nuijten, 
500 F.3d 1346, 1365 (Fed. Cir. 2007) (Linn, J., concurring-in-part and 
dissenting-in-part) (describing the printed matter doctrine as “potentially 
more apposite as a consequence of the ‘useful’ requirement of § 101”); 
Boggs v. Robertson, 13 U.S.P.Q. 214, 214 (D.C. Sup. Ct. 1931) (applying 
the doctrine as an extension of the abstract ideas exception); see also supra 
Section II.B (describing the doctrine’s complementary role to the exceptions 
for laws of nature, physical phenomena, and abstract ideas); Collins, supra, 
at 1402 (arguing that the abstract ideas exception “comes the closest to a 
source of support for the doctrine”). 
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III.  The Printed Matter Doctrine Precludes the Patentability of the 
Claimed Oligonucleotide Compositions 
  
A. The Inventive Contributions of the Claimed Oligonucleotide 
Compositions Subsist Merely in Stored Information 
 
As the printed matter doctrine is a generally applicable principle of 
patent law, see supra section II.A, amici do not consider it necessary to 
appeal to “the unique properties of DNA that distinguish it from all other 
chemicals and biological molecules found in nature” on which the district 
court’s opinion purportedly relies.  See Association for Molecular Pathology 
v. U. S. Patent & Trademark Office, 702 F. Supp. 2d 181, 228 (S.D.N.Y. 
2010).  Nor do amici appeal here to policy concerns expressed elsewhere 
about the impacts of oligonucleotide patenting on valuable downstream 
research.  See, e.g., Dan L. Burk & Mark A. Lemley, Policy Levers in Patent 
Law, 89 VA. L. REV. 1575, 1626 (2003); Andrew Chin, Research in the 
Shadow of DNA Patents, 87 J. PAT. & TRADEMARK OFF. SOC’Y 846, 857-58 
(2005); Yvonne Cripps, The Art and Science of Genetic Modification: Re-
Engineering Patent Law and Constitutional Orthodoxies, 11 IND. J. GLOBAL 
LEGAL STUD. 1, 5-7 (2004); Johanna Dennis, Divergence in Patent Systems, 
1 INT’L J. PRIVATE L. 268, 281 (2008); Donna M. Gitter, International 
Conflicts Over Patenting Human DNA Sequences in the
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the European Union, 76 N.Y.U. L. REV. 1623, 1667-71 (2001); Jon F. Merz 
et al., Diagnostic Testing Fails the Test: The Pitfalls of Patents Are 
Illustrated By the Case of Hemochromatosis, 415 NATURE 577 (2002); see 
also Keith Aoki, Distributive and Syncretic Motives in Intellectual Property 
Law, 40 U.C. DAVIS L. REV. 717, 797-98 (2007) (describing harms to 
biodiversity).  Moreover, amici fully agree with Myriad’s characterization of 
DNA as “a real and tangible molecule, a chemical composition made up of 
deoxyribonucleotides linked by a phosphodiester backbone” and offer no 
suggestion that “the term ‘DNA’ refers merely to information.”  702 F. 
Supp. 2d at 216.  What is germane to the printed matter doctrine, however, 
are the facts that a DNA molecule is a physical substrate capable of holding 
information, and that the claimed DNA oligonucleotide compositions exhibit 
no new and unobvious functional relationship between their sequence 
information and their molecular substrates. See supra section II.A. 
The synthesis and use of isolated DNA oligonucleotides as 
hybridization probes has been known in the published literature since at least 
1975.  See Edwin Mellor Southern, Detection of Specific Sequences Among 
DNA Fragments Separated by Gel Electrophoresis, 98 J. MOLECULAR 
BIOLOGY 503 (1975).  The claimed oligonucleotides differ from the 
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oligonucleotides used in prior art hybridization probe procedures only with 
respect to the nucleotide sequences carried thereon.  See, e.g., U.S. Patent 
No. 5,198,338, col. 3 (issued May 30, 1993) (describing the use of Southern 
hybridization with isolated DNA olignoucleotide probes “of a suitable 
hybridizable length (generally longer than 15 nucleotides)” for the detection 
of T-cell malignancy).  Thus, the inventive contributions of the claimed 
oligonucleotide compositions subsist merely in the nucleotide sequence 
information stored in the claimed molecules.  See Kevin Emerson Collins, 
Semiotics 101: Taking the Printed Matter Doctrine Seriously, INDIANA L.J. 
1379, 1390 (2010) (“The difference between a newly isolated and purified 
strand of DNA and prior art DNA molecules resides in the content of the 
DNA-as-information. . .”). 
By structure and function, DNA oligonucleotides are disposed to store 
nucleotide sequence information in a manner analogous in all relevant 
respects to other substrates that may be more intuitively recognizable as 
information storage media.  Structurally, characters comprising textual 
information are physically represented on a laser-printed page by defined 
patterns of toner powder fused to a paper surface.  See Laser Printer, 
WIKIPEDIA <http://en.wikipedia.org/wiki/Laser_printer> (accessed Nov. 28, 
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2010).  Similarly, nucleotide sequence information is physically represented 
in the DNA molecule by four defined types of submolecular units called 
“bases,” wherein each base is bonded to a 5-carbon sugar that has a 
phosphate group attached to form a sequential unit called a “nucleotide.”  
See In re O’Farrell, 853 F.2d 894, 896 (Fed. Cir. 1988).  The resulting 
structure in each case physically manifests the specific information stored in 
the substrate, thereby enabling that information to be retrieved. 
 Functionally, laser printing stores textual information on a paper 
substrate through a computer-automated procedure that sequences and 
controls the process of placing and fusing the toner powder onto the page.  
See Laser Printer, supra.  Analogously, automated oligonucleotide synthesis 
stores nucleotide sequence information in a DNA molecule through a 
computer-automated procedure that sequences and controls the process of 
placing and binding nucleotides onto the molecule, which is covalently 
bonded to a solid support.2  The user of an oligonucleotide synthesizer 
                                           
2
  Oligonucleotide synthesis dates back to the early 1950s, soon after the 
discovery of the structure of DNA.  See Daniel M. Brown, A Brief History of 
Oligonucleotide Synthesis, in 20 PROTOCOLS FOR OLIGONUCLEOTIDES AND 
ANALOGS 1, 1 (1993).  Phosphotriester technology for oligonucleotide 
synthesis was primarily developed in the 1960s and 1970s and refined and 
popularized in the 1980s.  See Brown, supra, at 7-9; see also Keiichi Itakura 
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merely has to type in the sequence and “press[] a few buttons.”   See Richard 
Pon, Solid-Phase Supports for Oligonucleotide Synthesis, in 20 PROTOCOLS 
FOR OLIGONUCLEOTIDES AND ANALOGS 465, 465 (1993).  Nucleotide 
sequence information can subsequently be retrieved from a DNA 
oligonucleotide using modern sequencing procedures.  See Enzo Biochem, 
Inc. v. Gen-Probe, Inc., 323 F.3d 956 (Fed. Cir. 2002) (finding that one of 
ordinary skill can use known sequencing techniques to obtain nucleotide 
sequences from deposited DNA molecules). 
While the fixation of nucleotide sequence information in the DNA 
molecule occurs on an intramolecular level, the microscopic scale of this 
phenomenon does not belie the fact that DNA oligonucleotides are 
analogous in structure and function to other physical substrates that store and 
                                                                                                                             
et al., Synthesis and Use of Synthetic Oligonucleotides, 53 ANN. REV. 
BIOCHEMISTRY 323, 353 (1984) (“[T]he chemical synthesis of 
oligodeoxyribonucleotides has become a routine laboratory procedure.”).  In 
phosphotriester synthesis, the most widely used methodology, there are four 
steps in each nucleotide addition, and at each step appropriate compounds 
are added and washed out as the reaction proceeds.  The four steps are: (1) 
de-blocking of the DMT group on the last nucleotide added, (2) coupling to 
the next nucleotide, (3) capping against any unreacted nucleotides, and (4) 
oxidation of the linkage to render it stable.  See Oligonucleotide Synthesis, 
WIKIPEDIA 
<http://en.wikipedia.org/wiki/Oligonucleotide_synthesis#Synthetic_cycle> 
(visited Nov. 28, 2010).   
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manifest information as printed matter, such as laser-printed paper.  Any 
structural differences between the claimed oligonucleotide compositions and 
prior art DNA oligonucleotides are simply the physical manifestation of 
differences in nucleotide sequence information as it is stored in the 
respective molecular substrates.  Under the printed matter doctrine, 
therefore, any inventive contributions of the claimed oligonucleotide 
contributions should be found to subsist merely in stored information. 
 
B. The Novelty and Nonobviousness Analyses of the Claimed 
Oligonucleotide Compositions Are Contingent on Inapposite 
Information-Management Considerations 
 
 As explained in section II.B supra, the printed matter doctrine serves 
to pre-empt the diversion of patent law’s novelty and nonobviousness 
analyses into information-management considerations unrelated to progress 
in the field of the underlying invention.  The analysis of the patentability of 
oligonucleotide probes is uniquely susceptible to such diversion, because of 
two interrelated facts.  First, as this court has recently explicitly recognized, 
general methods of making isolated DNA oligonucleotides of arbitrary 
sequence have long been well known.  See In re Gleave, 560 F.3d 1331, 
1336 (Fed. Cir. 2009) (finding prior art to be enabling based on applicant’s 
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admission that “it is well within the skill of an ordinary person in the art to 
make any oligodeoxynucleotide sequence”); Brown, supra note 2.  Second, 
large databases providing nucleotide sequence information, but not listing all 
oligonucleotide subsequences thereof, have been available to the public 
since the early 1980s.  See GenBank, WIKIPEDIA< http://en.wikipedia.org/ 
wiki/GenBank#History> (visited Nov. 28, 2010); David S. Roos, 
Bioinformatics: Trying to Swim in a Sea of Data, 291 SCIENCE 1260 (2001) 
(noting GenBank “continues to more than double in size every year”). 
 At least until recently, this court has characterized both of these facts 
as largely irrelevant to the novelty and nonobviousness analyses of claims to 
particular isolated DNA oligonucleotides.  In In re Deuel, 51 F.3d 1552 
(Fed. Cir. 1995), this court held that the availability of general methods of 
making isolated DNA molecules “is essentially irrelevant to the question 
whether the specific [claimed] molecules themselves would have been 
obvious” to one of ordinary skill.  Id. at 1559; but see In re Kubin, 561 F.3d 
1351, 1358-59 (Fed. Cir. 2009) (noting the Supreme Court’s repudiation of 
Deuel to the extent that Deuel foreclosed arguments that a combination of 
elements was “obvious to try”).  Databases of nucleotide sequences, without 
more, typically do not anticipate claims to isolated oligonucleotides 
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comprising specific subsequences thereof, because such databases usually do 
not teach all limitations of an isolated oligonucleotide claim, e.g., by listing 
the sequence of every such oligonucleotide.  See generally In re Gleave, 560 
F.3d at 1336-38 (discussing different treatment of lists and genera under 
anticipation case law). 
 Gleave implies that the patentability analysis of claimed DNA 
oligonucleotides would be very different if scientists were in the practice of 
publishing lists of oligonucleotide subsequences in addition to the full-length 
sequences from which they were derived.  In Gleave, this court reviewed the 
Patent Office’s rejection of a claim to an antisense DNA oligonucleotide 
substantially complementary to genes encoding two types of insulin-
dependent growth factor binding protein.  Id.  The examiner imposed, and 
the Board approved, a § 102(b) rejection over a reference that listed each of 
the more than 1400 fifteen-base-long sense oligonucleotides contained in 
one of the genes and suggested making antisense oligonucleotides capable of 
interacting with the listed sense oligonucleotides.  Id. at 1333-34.  Noting 
that “a person of ordinary skill in the art equipped with an IGFBP sequence 
is admittedly capable of envisioning how to make any antisense sequence,” 
this court found the reference to anticipate all of the listed sense 
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oligonucleotides and their antisense counterparts.  Id. at 1338. 
That the proliferation of nucleotide sequences in public databases has 
not been accompanied by equally extensive and particularized 
documentation of oligonucleotide sequences does not reflect limitations in 
the state of the art in biotechnology, but norms in scholarly communication.  
Given any long nucleotide sequence, it is a trivial matter to identify all of the 
oligonucleotides of a given length contained therein; to list all of them 
would contribute nothing to the advancement of science and be a frivolous 
waste of space.  It is not surprising that the lengthy oligonucleotide listing 
cited as prior art in Gleave was from a patent application rather than a 
professional scientific publication. 
 It is an equally trivial (though scientifically uninteresting) matter to 
list all oligonucleotide sequences of a given length that can be made with 
known synthesis techniques, and thereby to generate a defensive publication 
that anticipates a broad class of oligonucleotide compositions.  As one 
amicus has demonstrated, the potential impact of such defensive 
publications on the patentability of oligonucleotides is limited only by the 
capacity of digital storage media.  See Andrew Chin, Artful Prior Art and the 
Quality of DNA Patents, 57 ALA. L. REV. 975, 1021-23 (2006). 
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 In March 2002, Chin prepared a text document entitled “On the 
Preparation and Utilization of Isolated and Purified Oligonucleotides,” 
containing (1) a technical explanation of how to make and use isolated and 
purified oligonucleotides of arbitrary sequence (derived from the 
presumably enabling specifications of previously issued patents), and (2) a 
computer-generated list of 11 million nucleotide sequences 8 to 12 bases in 
length that could be made and used by the disclosed methods.  See id. at 
1036-38 & n. 410.  This document was recorded on CD-ROM and deposited 
in the University of North Carolina School of Law’s library, where it was 
indexed, cataloged and shelved under the Library of Congress subject 
heading for oligonucleotides on March 14, 2002.  See id. at 1010.  This 
“shotgun reference” has been effective § 102(b) prior art against 
oligonucleotide composition claims filed on or after March 15, 2003.3 
                                           
3
 See 35 U.S.C. § 102(b). 
 As of October 15, 2010, Chin’s publication has been cited in the 
prosecution history of 39 issued patents, including 35 whose applications 
originally contained oligonucleotide composition claims. See U.S. Patents 
Nos. 6946267, 6953669, 7049067, 7087733, 7090980, 7098192, 7105319, 
7108973, 7132233, 7166430, 7176181, 7186537, 7198898, 7229976, 
7291725, 7339041, 7342109, 7345161, 7393641, 7393950, 7407943, 
7414033, 7416725, 7468431, 7495094, 7514241, 7553618, 7589190, 
7618947, 7622455, 7678895, 7700574, 7709628, 7718628, 7732590, 
7737264, 7759318, 7759479.  In all 35 cases, the oligonucleotide 
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Fig. 1.  Impact of the Chin reference on patentability of 
oligonucleotides.  Chin, supra, at 1022. 
 
 Chin’s reference was limited to 11 million sequences only by the 
capacity of a CD-ROM in 2002.  As Fig. 1 illustrates, at any given time, the 
feasibility of producing a shotgun reference as effective prior art against 
                                                                                                                             
composition claims were either canceled or narrowed by amendment to 
exclude sequences of 8 to 12 bases in length.  In one case, the patent 
examiner also cited the Chin reference in a § 103 rejection of several method 
claims.  See U.S. Patent No. 7090980 (final rejection of Oct. 14, 2005). 
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oligonucleotides of a given length is dependent on the availability of high-
capacity, low-cost digital media.  In Fig. 1, the impact of Chin’s 2002 
reference is represented by the white segment that has been carved out of the 
shaded rectangle; the right scale indicates that as of 2003, broad claims to 
oligonucleotides of 8 to 12 bases were no longer patentable.  As the data 
points plotted against the left scale illustrate, continuing advances in 
information storage technology may be expected to make it feasible to 
generate and publish shotgun references covering oligonucleotides of ever-
increasing lengths. 
 There is a deep incongruity in these results.  Known methods of 
synthesizing arbitrary isolated DNA oligonucleotides represent a significant 
part of the state of the art in biotechnology.4  In contrast, the existence (or 
nonexistence) of shotgun references listing the sequences of arbitrary 
isolated oligonucleotides is of no significance to the state of the art in 
biotechnology.  The feasibility of generating and publishing a shotgun 
reference of a given scope is determined solely by the state of information 
storage technology.  Yet patent doctrine holds that such a sequence listing 
anticipates an oligonucleotide composition claim, see Gleave, 560 F.3d at 
                                           
4
 See Brown, supra note 2. 
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1336-38, while oligonucleotide synthesizers do not even render such a claim 
obvious.  See Deuel, 51 F.3d at 1559. 
 Chin’s reference (and the patent system’s response thereto) concretely 
demonstrates that the novelty and nonobviousness analyses of 
oligonucleotide composition claims are deeply and inextricably contingent 
on information-management considerations that are irrelevant to the state of 
the art in biotechnology.  The printed matter doctrine can serve its functional 
role by obviating such analyses.  See section II.B. 
 Amici acknowledge that the courts have not previously applied the 
printed matter doctrine to preclude the patenting of DNA molecules.  See 
Collins, supra, at 1389 n. 40 (noting that “printed matter challenges have not 
been brought against gene patents”).  Amici submit, however, that it has only 
been relatively recently that unrelated but contemporaneous developments in 
biotechnology and information technology have thrown the doctrinal 
incongruity described above into high relief.  It is only a matter of time until 
information technology supports the publication of shotgun references that 
foreclose the patenting of oligonucleotides of any given length.  The printed 
matter doctrine can declare an end to this irrelevant waiting game. 
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C. The Claimed Oligonucleotide Compositions Exhibit No New 
and Unobvious Functional Relationship Between the Sequence 
Information and the Molecular Substrate 
 
“Additional advantageous activity” may distinguish a claimed species 
as nonobvious over a known genus.  See In re Albrecht, 514 F.2d 1389 
(C.C.P.A. 1975).  While the specific utility of the claimed oligonucleotide 
compositions in clinical testing for breast cancer may represent “additional 
advantageous activity” in which nonobviousness subsists, this utility is not 
the result of a “new and unobvious functional relationship between the 
printed matter and the substrate.”  In re Gulack, 703 F.2d at 1386.  
Accordingly, the printed matter doctrine should be applied to invalidate the 
oligonucleotide composition claims. 
In Gulack, the claimed invention was an endless band on which had 
been printed the first P–1 significant digits in the repeating decimal 
expansion of 1/P, where P is a prime number.  See id. at 1383.  This number 
has the property that cyclic shifts of the digits produce integer multiples of 
the original number.5   See id.  The inventor claimed the band as “an 
educational and recreational mathematical device” that would display cyclic 
                                           
5
 For example, the decimal expansion of 1/7 is  .142857142857….  A cyclic 
shift of the number 142857 has the property that 428571=3*142857. 
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shifts of the original number, whose multiplicative properties might be used, 
inter alia, “to perform magic tricks or to display various aspects of number 
theory.”  See id.  The specification and claims included such embodiments 
as a belt, hatband, necklace, or ring.  See id.  
The examiner rejected several claims under the printed matter 
doctrine, and the Board affirmed, finding “no functional relationship of the 
printed material to the substrate.”  See id. at 1384.  This court reversed, 
finding that “the digits of Gulack’s invention are functionally related to the 
band.”  Id. at 1385.  The court reasoned: 
The appealed claims, on the other hand, require a 
particular sequence of digits to be displayed on the outside 
surface of a band. These digits are related to the band in two 
ways: (1) the band supports the digits; and (2) there is an 
endless sequence of digits — each digit residing in a unique 
position with respect to every other digit in an endless loop. 
Thus, the digits exploit the endless nature of the band. 
 
Id. at 1386-87. 
Crucial to the court’s analysis was its finding that “there is an endless 
sequence of digits” that could not have been stored on anything other than a 
distinctive kind of substrate; i.e., one with an “endless nature.”  Gulack’s 
specification, however, teaches that “the sequence of digits imprinted on the 
band” is the finite sequence of P–1 digits described above.  See id. at 1383.  
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The Gulack court thus appears to have construed “the digits of Gulack’s 
invention” as intrinsically incorporating a special mathematical property that 
could be manifested only by also including all cyclic shifts of those digits. 
In contrast, the nucleotide sequences of the claimed oligonucleotide 
compositions do not possess any intrinsic property that necessitates a 
distinctive kind of substrate.  An oligonucleotide synthesizer fixes the 
sequence information of the claimed oligonucleotides into the substructures 
of a DNA molecule in the same way as it processes any other sequence 
information.  See supra note 2. 
Amici acknowledge that the claimed oligonucleotides manifest higher-
order structures that dispose them to hybridize specifically with the 
complementary DNA sequences described in the specification as associated 
with various human breast and ovarian cancers.  From a functional 
standpoint, however, the causal disposition of oligonucleotides to hybridize 
with complementary DNA sequences — the only causal disposition that the 
oligonucleotides of each of the claimed genera have in common6 — is 
                                           
6
 In contrast to oligonucleotides, longer DNA molecules that encode proteins 
with metabolic functions may have both meaning that is semantic and 
information content that is non-semantic, see Peter Godfrey-Smith, Genes 
Do Not Code for Phenotypic Traits, in CONTEMPORARY DEBATES IN 
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common to all oligonucleotides, and is neither new nor unobvious.  See In re 
Deuel, 51 F.3d at 1554-55 (explaining that DNA probes “exploit the fact that 
the bases in DNA always hybridize in complementary pairs”).  The sequence 
information of the claimed oligonucleotides possesses no intrinsic property 
that distinguishes the functional properties of their underlying substrates 
from those of other oligonucleotides. 
To the extent that a hybridization reaction involving a claimed 
oligonucleotide is recognized as having specific utility, it is by virtue of the 
semantic properties that scientists have attached to the complementary DNA 
sequence, not a new and unobvious functional relationship between the 
sequence information and the molecular substrate.  See U.S. Patent No. 
5,747,282, col. 7 (describing the observation of “large extended families . . . 
with multiple cases of breast cancer” to support scientists’ inferences 
regarding the locus of the BRCA1 gene); see also Godfrey-Smith, supra 
note 6, at 283 (arguing that apart from protein synthesis, causal claims 
                                                                                                                             
PHILOSOPHY OF SCIENCE 275, 281-94 (Christopher Hitchcock ed. 2004), and 
therefore might not be covered by the printed matter doctrine.  Cf. In re 
Fisher, 421 F.3d 1365, 1373 (Fed. Cir. 2005) (finding expressed sequence 
tags that were “unable to provide any information about the overall structure 
let alone the function of the underlying [protein-encoding] gene” to lack 
patentable utility as research tools). 
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linking genes and phenotypic traits are grounded in semantic description).  
While hybridization reactions involving the claimed oligonucleotide probes 
may impart new and unobvious information regarding cancer, such 
information is useful and intelligible only to the human mind and cannot 
confer patentability.  See In re Lowry, 32 F.3d 1579 (Fed. Cir. 1994) (citing 
In re Bernhart, 417 F.2d 1395, 1399 (C.C.P.A. 1969)) (“The printed matter 
cases ‘dealt with claims defining as the invention certain novel arrangements 
of printed lines or characters, useful and intelligible only to the human 
mind.’”); see also Collins, supra, at 1383 (“Standing alone, newly invented 
semiotic meanings are not eligible for patent protection.  Similarly, attaching 
new semiotic meanings to old worldly things does not make the worldly 
things patentable.”). 
 
CONCLUSION 
For the foregoing reasons, the court should affirm the district court’s 
judgment of invalidity of claims 5 and 6 and hold that the printed matter 
doctrine precludes the patenting of oligonucleotides capable of being 
synthesized by known general methods. 
 33
 
 
      Respectfully submitted, 
 
December 7, 2010     _________________________ 
       ANDREW CHIN 
       University of North Carolina 
          School of Law 
       160 Ridge Road 
Chapel Hill, NC 27599-3380 
Research Assistants    (919) 962-4116  
to Professor Chin     Counsel of Record for 
SHAHID KHAN     Amici Curiae Scholars of  
JOHN KIVUS      Biotechnology Patent Law 
 34
 
 
APPENDIX A 
List of Signatories 
 
 
Professor Keith Aoki 
University of California at Davis School of Law 
 
Professor Adam Candeub 
Michigan State University School of Law 
 
Professor Andrew Chin 
University of North Carolina School of Law 
 
Professor Yvonne Cripps 
University of Indiana School of Law 
 
Professor Johanna Dennis 
Vermont Law School 
 
Professor Llewellyn Joseph Gibbons 
University of Toledo College of Law 
 
Professor Donna M. Gitter 
Associate Professor of Law 
Zicklin School of Business 
Baruch College, City University of New York 
 
Professor Jon Merz 
Senior Fellow, Center for Medical Ethics 
Associate Chair for Faculty Affairs, Department of Medical Ethics 
University of Pennsylvania School of Medicine 
 
 
 35
 
 
CERTIFICATE OF FILING AND SERVICE 
I hereby certify that on this 7th day of December, 2010, I caused 
twelve true and correct copies of the foregoing Brief for Amicus Curiae 
Scholars of Biotechnology Patent Law in Support of Plaintiffs-Appellees 
and an original Entry of Appearance of Andrew Chin to be mailed via 
Federal Express to the Court, and for two true and correct copies of the Brief 
and one true and correct copy of the Appearance to be served via first class 
U.S. mail, postage prepaid, upon the following counsel of record: 
 
Christopher A. Hansen 
American Civil Liberties Union 
125 Broad Street, 18th Floor 
New York, NY 10004 
chansen@aclu.org 
Counsel for Plaintiffs-Appellees 
 
Gregory A. Castanias 
Jones Day 
51 Louisiana Avenue, N.W. 
Washington, D.C. 20001 
gcastanias@jonesday.com 
Counsel for Defendants-Appellants 
 
Mary M. Calkins 
Foley and Lardner 
3000 K Street, N.W., Suite 500 
Washington, DC 20007 
Counsel for Amicus Alnylam 
Pharmaceuticals 
 
Barbara R. Rudolph 
Finnegan, Henderson, Farabow, 
Garrett & Dunner 
901 New York Avenue, N.W. 
Suite 1100 
Washington, DC 20001-4413 
Counsel for Amicus American 
Intellectual Property Law 
Association 
 
Seth P. Waxman 
Wilmer Hale 
1875 Pennsylvania Avenue, N.W. 
Washington, DC 20006 
Counsel for Amici Biotech 
Industry +Organization et al. 
 
 36
 
 
Erik P. Belt 
McCarter & English 
265 Franklin Street 
Boston, MA 02110 
Counsel for Amicus Boston Patent 
Law Association 
 
Christopher M. Holman 
5100 Rockhill Road 
Kansas City, MO 64110 
Counsel for Amici Christopher 
Holman et al. 
 
Jennifer Gordon 
Baker Botts 
30 Rockefeller Center 
New York, NY 10112 
Counsel for Amicus Croplife 
International 
 
Maxim H. Waldbaum 
Schiff Hardin 
900 Third Avenue, 23rd Floor 
New York, NY 10022 
Counsel for Amicus Fédération 
Internationale des Conseils en 
Propriété Industrielle (FICPI) 
 
David S. Forman 
Finnegan, Henderson, Farabow, 
Garrett & Dunner 
901 New York Avenue, N.W. 
Washington, DC 20001-4413 
Counsel for Amicus Genetic 
Alliance 
 
William G. Gaede, III 
McDermott, Will & Emery 
275 Middlefield Rd., Suite 100 
Menlo Park, CA 94025 
Counsel for Amici Genomic Health 
et al. 
 
J. Timothy Keane 
Harness, Dickey & Pierce 
7700 Bonhomme Avenue, Suite 
400 
St. Louis, MO 63105 
Counsel for Amici Gilead Sciences 
et al. 
 
Herbert C. Wamsley 
McDonnell, Boehnen, Hulbert & 
Berghoff 
300 South Wacker Drive 
Chicago, Illinois 60606 
Counsel for Amicus Intellectual 
Property Owners Association 
 
Brian R. Dorn 
Merchant & Gould 
80 South 8th Street, Suite 3200 
Minneapolis, MN 55402-2215 
Counsel for Amicus Kane Biotech 
 
Judy Deleon Jarecki-Black 
Merial Limited 
3239 Satellite Blvd. 
Duluth, GA 30096 
Counsel for Amicus Merial 
Limited 
 
 37
 
 
Kent D. McClure 
Animal Health Institute 
1325 G Street, NW, Suite 700 
Washington, DC 20005 
Counsel for Amicus Animal Health 
Institute 
 
Aaron Stiefel 
Kaye Scholer 
425 Park Avenue 
New York, NY 10022 
Counsel for Amicus Novartis Corp. 
 
Kurt G. Calia 
Covington & Burling 
1201 Pennsylvania Avenue, N.W. 
Washington, DC 20004-2401 
Counsel for Amicus 
Pharmaceutical Research and 
Manufacturers of America 
 
Jacqueline D. Wright-Bonilla 
Foley and Lardner 
3000 K Street, N.W., Suite 500 
Washington, DC 20007 
Counsel for Amici Rosetta 
Genomics et al. 
 
Mark R. Freeman 
U.S. Department of Justice 
950 Pennsylvania Avenue, N.W., 
Room 7644 
Washington, DC 20530-0001 
Counsel for Amicus United States 
 
Ann M. McCrackin 
University of New Hampshire 
School of Law 
2 White Street 
Concord, NH 03301 
Counsel for Amicus University of 
New Hampshire School of Law 
 
 
 
_________________________ 
       ANDREW CHIN 
       University of North Carolina 
          School of Law 
       160 Ridge Road 
       Chapel Hill, NC 27599-3380 
       (919) 962-4116 
Counsel of Record for Amici 
Curiae Scholars of 
Biotechnology Patent Law 
 38
 
 
CERTIFICATE OF COMPLIANCE 
 
I certify that the foregoing Brief for Amicus Curiae Scholars of 
Biotechnology Patent Law contains 6,719 words, including footnotes, and 
excluding the parts of the brief exempted by FRAP 32(a)(7)(B)(iii), as 
measured by the word processing software used to prepare this brief. 
I certify that this brief complies with the typeface requirements of 
Federal Rule of Appellate Procedure 32(a)(5) and the type style 
requirements of the Federal Rule of Appellate Procedure 32(a)(6), because it 
has been prepared in a proportionally spaced typeface using Times New 
Roman 14 point font. 
 
 
Dated:  December 7, 2010    
 
       _________________________ 
       ANDREW CHIN 
       University of North Carolina 
          School of Law 
       160 Ridge Road 
       Chapel Hill, NC  27599-3380 
       (919) 962-4116 
Counsel of Record for Amici 
Curiae Scholars of 
Biotechnology Patent Law 
